[go: up one dir, main page]

WO2008106047A3 - Composés de carbamate - Google Patents

Composés de carbamate Download PDF

Info

Publication number
WO2008106047A3
WO2008106047A3 PCT/US2008/002309 US2008002309W WO2008106047A3 WO 2008106047 A3 WO2008106047 A3 WO 2008106047A3 US 2008002309 W US2008002309 W US 2008002309W WO 2008106047 A3 WO2008106047 A3 WO 2008106047A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbamate compounds
carbamate
compounds
useful
formula
Prior art date
Application number
PCT/US2008/002309
Other languages
English (en)
Other versions
WO2008106047A2 (fr
Inventor
Yaoquan Liu
Hong Fu
Original Assignee
Kosan Biosciences Inc
Yaoquan Liu
Hong Fu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc, Yaoquan Liu, Hong Fu filed Critical Kosan Biosciences Inc
Priority to JP2009551992A priority Critical patent/JP2010519337A/ja
Priority to CN200880013458A priority patent/CN101711154A/zh
Priority to EP08725899A priority patent/EP2124927A2/fr
Publication of WO2008106047A2 publication Critical patent/WO2008106047A2/fr
Publication of WO2008106047A3 publication Critical patent/WO2008106047A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de carbamate ayant une structure représentée par la formule I (dans laquelle R1, R2, R3, R4, R5 et R6 sont tels que définis dans le présent document), lesdits composés étant utiles en tant qu'agents antitumoraux.
PCT/US2008/002309 2007-02-26 2008-02-20 Composés de carbamate WO2008106047A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009551992A JP2010519337A (ja) 2007-02-26 2008-02-20 カルバメート化合物
CN200880013458A CN101711154A (zh) 2007-02-26 2008-02-20 氨基甲酸酯化合物
EP08725899A EP2124927A2 (fr) 2007-02-26 2008-02-20 Composés de carbamate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90377007P 2007-02-26 2007-02-26
US60/903,770 2007-02-26

Publications (2)

Publication Number Publication Date
WO2008106047A2 WO2008106047A2 (fr) 2008-09-04
WO2008106047A3 true WO2008106047A3 (fr) 2008-10-16

Family

ID=39721789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002309 WO2008106047A2 (fr) 2007-02-26 2008-02-20 Composés de carbamate

Country Status (5)

Country Link
US (1) US7795457B2 (fr)
EP (1) EP2124927A2 (fr)
JP (1) JP2010519337A (fr)
CN (1) CN101711154A (fr)
WO (1) WO2008106047A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049378A1 (fr) * 2007-10-17 2009-04-23 Qbiotics Limited Dérivés de lactone
WO2010068947A2 (fr) 2008-12-12 2010-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs d'export nucléaire de topoisomérase ii alpha
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
DK3333164T3 (da) 2011-07-29 2023-09-18 Karyopharm Therapeutics Inc Hydrazide containing nuclear transport modulators and uses thereof
CN102898363B (zh) * 2011-10-13 2014-04-09 南京圣和药业有限公司 氨基甲酸酯类化合物及其在抗肿瘤药物中的应用
EP3698782B1 (fr) 2012-01-06 2024-05-15 H. Lundbeck A/S Composés carbamates pour utilisation en thérapie
WO2013170068A2 (fr) 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Modulateurs du transport nucléaire et leurs utilisations
WO2014144772A1 (fr) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
HUE042800T2 (hu) 2013-06-21 2019-07-29 Karyopharm Therapeutics Inc 1,2,4-triazolok mint nukleáris transzport modulátorok és ezek alkalmazása
AU2015301484B2 (en) 2014-08-15 2020-02-20 Karyopharm Therapeutics Inc. Polymorphs of selinexor
ES2878041T3 (es) 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
AU2016262459A1 (en) 2015-05-11 2017-12-21 H. Lundbeck A/S. Methods of treating inflammation or neuropathic pain
EP3397633A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2018098472A1 (fr) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Inhibiteurs de crm1 pour le traitement de l'épilepsie
GEP20227443B (en) 2018-05-15 2022-11-25 H Lundbeck As Magl inhibitors
CN111170932A (zh) * 2020-01-13 2020-05-19 大连九信精细化工有限公司 一种2-氨甲基-5-三氟甲基吡啶盐的制备方法
JP2023523219A (ja) 2020-04-21 2023-06-02 ハー・ルンドベック・アクチエゼルスカベット モノアシルグリセロールリパーゼ阻害剤の合成

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021870A1 (fr) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives de l'erythromycine a 11,12-carbamate
US6420591B1 (en) * 1999-10-04 2002-07-16 University Of Medicine And Dentistry Of New Jersey Carbamates and compositions thereof, and methods for their use for treating cancer, inflammation, or a viral infection
US20050272727A1 (en) * 2004-06-03 2005-12-08 Steven Dong Leptomycin compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792522A (en) 1983-12-12 1988-12-20 Bristol-Myers Company Rigolettone antitumor complex
US4771070A (en) 1984-08-21 1988-09-13 Warner-Lambert Company CL-1957A antibiotic compound
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AU2001294511A1 (en) 2000-06-30 2002-01-08 The Regents Of The University Of California New strategy for leukemia therapy
US20050203174A1 (en) 2004-03-09 2005-09-15 Kosan Biosciences, Inc. Combination therapies using leptomycin B
WO2007033214A2 (fr) 2005-09-12 2007-03-22 Kosan Biosciences Incorporated Esters de composes de la famille de la leptomysine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021870A1 (fr) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives de l'erythromycine a 11,12-carbamate
US6420591B1 (en) * 1999-10-04 2002-07-16 University Of Medicine And Dentistry Of New Jersey Carbamates and compositions thereof, and methods for their use for treating cancer, inflammation, or a viral infection
US20050272727A1 (en) * 2004-06-03 2005-12-08 Steven Dong Leptomycin compounds

Also Published As

Publication number Publication date
US7795457B2 (en) 2010-09-14
CN101711154A (zh) 2010-05-19
EP2124927A2 (fr) 2009-12-02
WO2008106047A2 (fr) 2008-09-04
US20080214617A1 (en) 2008-09-04
JP2010519337A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2008106047A3 (fr) Composés de carbamate
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
WO2007133352A3 (fr) Inhibiteurs de kinase macrocycliques
WO2008126933A3 (fr) Procédé de production de composé amide
WO2006058700A8 (fr) Derives d'acetamides employes en tant que fongicides
WO2005074603A3 (fr) Utilisation d'aminobenzoxazoles comme agents therapeutiques
WO2009030469A8 (fr) Nouveaux fongicides
EP1911743B8 (fr) Composé d'amine cyclique
WO2009049716A8 (fr) Nouveaux fongicides
WO2009019015A8 (fr) Nouveaux herbicides
WO2007028135A3 (fr) Composes a base d'imidazopyridine
WO2009048101A1 (fr) Composé amide
WO2008122375A3 (fr) Dérivés d'arzlisoxayoline insecticides
WO2007030582A3 (fr) Inhibiteurs d'ikur acycliques
EA201000544A1 (ru) Производные спирогетероциклического пирролидиндиона, применимые в качестве пестицидов
WO2008110355A8 (fr) Dérivés de quinoléine en tant que fongicides
TW200730486A (en) Organic sulfur compounds and use thereof
TW200637837A (en) Fungicides
WO2007061923A3 (fr) Activateurs de la glucokinase
WO2009057079A3 (fr) Nouveaux dérivés de pyrimidine
GB0521508D0 (en) Organic compounds
WO2008153154A1 (fr) Composé cyclique, matériau de base pour résine photosensible et composition pour résine photosensible
WO2007062308A3 (fr) Inhibiteurs de cetp heterocycliques
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2005087724A3 (fr) Nouvelles hydroxy-6-phenylphenanthridines a substitution amido

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013458.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725899

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008725899

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5418/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009551992

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE